There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Aerovate Therapeutics (AVTE – Research Report), Antibe Therapeutics (ATBPF – Research Report) and Oncolytics Biotech (ONCY – Research Report) with bullish sentiments.
Aerovate Therapeutics (AVTE)
In a report released today, Andreas Argyrides from Wedbush reiterated a Buy rating on Aerovate Therapeutics, with a price target of $48.00. The company’s shares closed last Tuesday at $14.00, close to its 52-week low of $13.81.
According to TipRanks.com, Argyrides is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aerovate Therapeutics with a $32.33 average price target, an 115.5% upside from current levels. In a report released yesterday, Jefferies also maintained a Buy rating on the stock with a $22.00 price target.
See the top stocks recommended by analysts >>
Antibe Therapeutics (ATBPF)
Maxim Group analyst Naz Rahman maintained a Buy rating on Antibe Therapeutics yesterday and set a price target of C$2.00. The company’s shares closed last Monday at $0.41.
According to TipRanks.com, Rahman has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Antibe Therapeutics with a $1.49 average price target, a 258.3% upside from current levels. In a report released yesterday, Echelon Wealth Partners also assigned a Buy rating to the stock with a C$2.00 price target.
Oncolytics Biotech (ONCY)
Maxim Group analyst Jason McCarthy maintained a Buy rating on Oncolytics Biotech yesterday and set a price target of $5.00. The company’s shares closed last Tuesday at $2.06.
According to TipRanks.com, McCarthy has 0 stars on 0-5 stars ranking scale with an average return of
Oncolytics Biotech has an analyst consensus of Strong Buy, with a price target consensus of $7.33, which is a 259.3% upside from current levels. In a report released yesterday, JonesTrading also maintained a Buy rating on the stock with a C$9.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AVTE:
